{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:58:26Z","timestamp":1790423906574,"version":"4.1.0"},"reference-count":148,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T00:00:00Z","timestamp":1788739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Italian Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Preclinical research in cancer therapy-related cardiovascular toxicity (CTR-CVT) is a major domain of cardio-oncology and has provided biological explanation for the cardiovascular adverse effects of many cancer therapies. However, the choice of the experimental models to investigate the mechanisms of CTR-CVT is often based on personal experience and opinion, rather than on established principles and available evidence. Moreover, presentation of methods and results is frequently approximate. This Scientific Statement outlines potential quality standards regarding methodology and reporting in preclinical cardio-oncology research, with the goal of promoting accurate, reliable, and reproducible studies. Quality standards are distinguished in first-tier, when considered essential for robustness unless there is a strong justification for their omission, and second-tier standards, when desirable, but not necessary. First-tier standards ensure credible, self-sustaining research, while second-tier ones enhance quality of investigations and accelerate understanding of CTR-CVT. Adherence to the proposed quality standards is expected to benefit researchers embarking on new investigations, facilitate funding allocation, and inform the development of novel oncological therapies, eventually moving cardio-oncology science forward.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehag609","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T01:26:03Z","timestamp":1788744363000},"source":"Crossref","is-referenced-by-count":0,"title":["Quality standards for preclinical research in cardio-oncology"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7167-7287","authenticated-orcid":false,"given":"Pietro","family":"Ameri","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of Genova , Viale Benedetto XV, Genoa 6\u201316132 ,","place":["Italy"]},{"name":"Cardiovascular Translational Unit, IRCCS Azienda Ospedaliera Metropolitana , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalinda","family":"Madonna","sequence":"additional","affiliation":[{"name":"Department of Surgical, Medical and Molecular Pathology and Critical Area, Cardiology Division, University of Pisa , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambra","family":"Costa","sequence":"additional","affiliation":[{"name":"Cardiovascular Translational Unit, IRCCS Azienda Ospedaliera Metropolitana , Genoa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uri","family":"Amit","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Department of Radiation Oncology, Tel Aviv Medical Center , Tel Aviv ,","place":["Israel"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Andreadou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4967-9918","authenticated-orcid":false,"given":"Aarti","family":"Asnani","sequence":"additional","affiliation":[{"name":"Cardio-Oncology Section, Division of Cardiovascular Medicine, Beth Israel Deaconess Medical Center , Boston, MA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9616-0006","authenticated-orcid":false,"given":"Paul W","family":"Burridge","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Center for Pharmacogenomics, Feinberg School of Medicine, Northwestern University , Chicago, IL ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7394-1173","authenticated-orcid":false,"given":"Carolina","family":"Balbi","sequence":"additional","affiliation":[{"name":"Center for Molecular Cardiology, University of Zurich , Schlieren ,","place":["Switzerland"]},{"name":"Department of Internal Medicine, Cantonal Hospital of Baden , Baden ,","place":["Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4238-4183","authenticated-orcid":false,"given":"Gilles W","family":"De Keulenaer","sequence":"additional","affiliation":[{"name":"Laboratory of Physiopharmacology, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, Campus Drie Eiken, University of Antwerp , Antwerp ,","place":["Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"Evans","sequence":"additional","affiliation":[{"name":"William Harvey Research Institute, Barts & The London Faculty of Medicine & Dentistry, Queen Mary University of London , London ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1193-5296","authenticated-orcid":false,"given":"Alessandra","family":"Ghigo","sequence":"additional","affiliation":[{"name":"Molecular Biotechnology Center Guido Tarone, Department of Molecular Biotechnology and Health Sciences, University of Torino , Turin ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borja","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER-CV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz H","family":"Lehmann","sequence":"additional","affiliation":[{"name":"Department for Cardiology, Angiology, and Pneumology, Heidelberg University Hospital , Heidelberg ,","place":["Germany"]},{"name":"German Centre for Cardiovascular Research (DZHK), Partner Site Heidelberg\/Mannheim ,","place":["Germany"]},{"name":"German Cancer Research Center (DKFZ) , Heidelberg ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), CIBER-CV , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5678-6175","authenticated-orcid":false,"given":"Giorgio","family":"Minotti","sequence":"additional","affiliation":[{"name":"Universit\u00e0 and Fondazione Policlinico Universitario Campus Bio-Medico , Rome ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter C","family":"Meijers","sequence":"additional","affiliation":[{"name":"Erasmus MC, Cardiovascular Institute, Thorax Center, Department of Cardiology , Rotterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Morel","sequence":"additional","affiliation":[{"name":"Laboratory of Signalling and Cardiovascular Pathophysiology, Faculty of Pharmacy, Universit\u00e9 Paris Saclay , Paris ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doan","family":"Ngo","sequence":"additional","affiliation":[{"name":"The University of Newcastle , Newcastle ,","place":["Australia"]},{"name":"Heart and Stroke Program, Hunter Medical Research Institute , Newcastle ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7044-2985","authenticated-orcid":false,"given":"June-Wha","family":"Rhee","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, City of Hope Comprehensive Cancer Center , Duarte, CA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol Ann","family":"Remme","sequence":"additional","affiliation":[{"name":"Department of Experimental Cardiology, Amsterdam UMC, University of Amsterdam , Amsterdam ,","place":["The Netherlands"]},{"name":"Amsterdam Cardiovascular Sciences, Heart Failure and Arrhythmias, Academic Medical Center , Amsterdam ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo Gabriele","family":"Tocchetti","sequence":"additional","affiliation":[{"name":"Cardio-Pulmonary Onco-Immunology, Department of Internal Medicine and Clinical Complexity, Department of Translational Medical Sciences, Federico II University , Naples ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"van Der Meer","sequence":"additional","affiliation":[{"name":"Department of Cardiology, University Medical Center Groningen, University of Groningen , Groningen ,","place":["The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n V","family":"Varga","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Pharmacotherapy, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"Center for Pharmacology and Drug Research and Development, Semmelweis University , Budapest ,","place":["Hungary"]},{"name":"HCEMM-SU Cardiometabolic Immunology Research Group , Budapest ,","place":["Hungary"]},{"name":"MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group , Budapest ,","place":["Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis I","family":"Verginadis","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard M","family":"Walls","sequence":"additional","affiliation":[{"name":"Patrick G. Johnston Centre for Cancer Research, Queen's University Belfast , Belfast, Northern Ireland ,","place":["UK"]},{"name":"Cancer Centre Belfast City Hospital, Belfast Health & Social Care Trust , Belfast, Northern Ireland ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1282-9276","authenticated-orcid":false,"given":"Johann","family":"Wojta","sequence":"additional","affiliation":[{"name":"Ludwig Boltzmann Institute of Cardiovascular Research , Vienna ,","place":["Austria"]},{"name":"Department of Internal Medicine II, Medical University of Vienna , Vienna ,","place":["Austria"]},{"name":"Core Facilities, Medical University of Vienna , Vienna ,","place":["Austria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"L\u00f3pez Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Cardiology Department, Cardio-Oncology Unit, La Paz University Hospital and IdiPAZ Research Institute , Madrid ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,7]]},"reference":[{"key":"2026092607012748500_ehag609-B1","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/ejhf.3102","article-title":"European society of cardiology core curriculum for cardio-oncology","volume":"26","author":"L\u00f3pez-Fern\u00e1ndez","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B2","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1161\/CIRCULATIONAHA.117.030352","article-title":"Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth","volume":"138","author":"Li","year":"2018","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B3","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1038\/nm.4087","article-title":"Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity","volume":"22","author":"Burridge","year":"2016","journal-title":"Nat Med"},{"key":"2026092607012748500_ehag609-B4","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1161\/CIRCULATIONAHA.118.037357","article-title":"Human-induced pluripotent stem cell model of trastuzumab-induced cardiac dysfunction in patients with breast cancer","volume":"139","author":"Kitani","year":"2019","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B5","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1093\/eurheartj\/ehae188","article-title":"Rescue of cardiac dysfunction during chemotherapy in acute myeloid leukaemia by blocking IL-1\u03b1","volume":"45","author":"Zhou","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B6","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1002\/ejhf.3636","article-title":"Update on preclinical models of cancer therapy-related cardiac dysfunction: challenges and perspectives. A scientific statement of the Heart Failure Association (HFA) of the ESC, the ESC Council of Cardio-Oncology, and the ESC Working Group on Cellular Biology of the Heart","volume":"27","author":"Ghigo","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B7","doi-asserted-by":"publisher","first-page":"E21","DOI":"10.1161\/RES.0000000000000473","article-title":"Preclinical models of cancer therapy-associated cardiovascular toxicity: a scientific statement from the American Heart Association","volume":"129","author":"Asnani","year":"2021","journal-title":"Circ Res"},{"key":"2026092607012748500_ehag609-B8","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B9","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1093\/cvr\/cvz010","article-title":"ESC working group on cellular biology of the heart: position paper for cardiovascular research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure","volume":"115","author":"Madonna","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B10","doi-asserted-by":"publisher","first-page":"3907","DOI":"10.1111\/bph.15868","article-title":"Planning experiments: updated guidance on experimental design and analysis and their reporting III","volume":"179","author":"Curtis","year":"2022","journal-title":"Br J Pharmacol"},{"key":"2026092607012748500_ehag609-B11","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1093\/cvr\/cvab370","article-title":"Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart","volume":"118","author":"van der Velden","year":"2022","journal-title":"Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1093\/cvr\/cvaa110","article-title":"Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function","volume":"117","author":"Zacchigna","year":"2021","journal-title":"Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00395-018-0696-8","article-title":"Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection","volume":"113","author":"B\u00f8tker","year":"2018","journal-title":"Basic Res Cardiol"},{"key":"2026092607012748500_ehag609-B14","doi-asserted-by":"publisher","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol"},{"key":"2026092607012748500_ehag609-B15","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.jacc.2019.05.024","article-title":"Cardiac MRI endpoints in myocardial infarction experimental and clinical trials: JACC scientific expert panel","volume":"74","author":"Ibanez","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2026092607012748500_ehag609-B16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s00395-025-01102-3","article-title":"IMproving preclinical assessment of cardioprotective therapies (IMPACT): a small animal acute myocardial infarction randomized-controlled multicenter study on the effect of ischemic preconditioning","volume":"120","author":"Hernandez-Resendiz","year":"2025","journal-title":"Basic Res Cardiol"},{"key":"2026092607012748500_ehag609-B17","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1093\/eurheartj\/ehad623","article-title":"Preclinicaltrials.eu: prospective registration of animal studies","volume":"44","author":"Menon","year":"2023","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B18","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE\u2019s risk of bias tool for animal studies","volume":"14","author":"Hooijmans","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026092607012748500_ehag609-B19","author":"Welcome to the SciRAP platform! | Karolinska Institutet"},{"key":"2026092607012748500_ehag609-B20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1002\/ejhf.3709","article-title":"How to facilitate seamless translation from basic concepts to new heart failure drugs. A scientific statement of the heart failure association of the ESC","volume":"27","author":"Tocchetti","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.yjmcc.2021.12.007","article-title":"Systematic transcriptomic and phenotypic characterization of human and murine cardiac myocyte cell lines and primary cardiomyocytes reveals serious limitations and low resemblances to adult cardiac phenotype","volume":"165","author":"On\u00f3di","year":"2022","journal-title":"J Mol Cell Cardiol"},{"key":"2026092607012748500_ehag609-B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","article-title":"The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy","volume":"106","author":"De Keulenaer","year":"2010","journal-title":"Circ Res"},{"key":"2026092607012748500_ehag609-B23","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","article-title":"Cardiovascular toxicities of immune therapies for cancer\u2014a scientific statement of the heart failure association (HFA) of the ESC and the ESC council of cardio-oncology","volume":"26","author":"Tocchetti","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B24","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s44161-022-00028-6","article-title":"Single-cell transcriptomics reveals cell-type-specific diversification in human heart failure","volume":"1","author":"Koenig","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B25","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1111\/bph.15984","article-title":"Characterization of immune checkpoint inhibitor-induced cardiotoxicity reveals interleukin-17A as a driver of cardiac dysfunction after anti-PD-1 treatment","volume":"180","author":"Gergely","year":"2023","journal-title":"Br J Pharmacol"},{"key":"2026092607012748500_ehag609-B26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1093\/toxsci\/kfu057","article-title":"An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity","volume":"140","author":"Cove-Smith","year":"2014","journal-title":"Toxicol Sci"},{"key":"2026092607012748500_ehag609-B27","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B28","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0079543","article-title":"Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice","volume":"8","author":"ElZarrad","year":"2013","journal-title":"PLoS One"},{"key":"2026092607012748500_ehag609-B29","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1093\/eurheartj\/ehae105","article-title":"Heart failure pharmacotherapy and cancer: pathways and pre-clinical\/clinical evidence","volume":"45","author":"Sayour","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B30","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/cvr\/cvz108","article-title":"Intravenous administration of cardiac progenitor cell-derived exosomes protects against doxorubicin\/trastuzumab-induced cardiac toxicity","volume":"116","author":"Milano","year":"2020","journal-title":"Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B31","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.658790","article-title":"Structural and electrophysiological changes in a model of cardiotoxicity induced by anthracycline combined with trastuzumab","volume":"12","author":"Altomare","year":"2021","journal-title":"Front Physiol"},{"key":"2026092607012748500_ehag609-B32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.echo.2014.01.014","article-title":"Doxorubicin and trastuzumab regimen induces biventricular failure in mice","volume":"27","author":"Milano","year":"2014","journal-title":"J Am Soc Echocardiogr"},{"key":"2026092607012748500_ehag609-B33","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/ejhf.2029","article-title":"Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"22","author":"de Boer","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B34","doi-asserted-by":"publisher","first-page":"10436","DOI":"10.1073\/pnas.1601650113","article-title":"Oncometabolite D-2-hydroxyglutarate impairs \u03b1-ketoglutarate dehydrogenase and contractile function in rodent heart","volume":"113","author":"Karlstaedt","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2026092607012748500_ehag609-B35","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1161\/CIRCULATIONAHA.109.902221","article-title":"Juvenile exposure to anthracyclines impairs cardiac progenitor cell function and vascularization resulting in greater susceptibility to stress-induced myocardial injury in adult mice","volume":"121","author":"Huang","year":"2010","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B36","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jacbts.2017.12.007","article-title":"Increased afterload augments sunitinib-induced cardiotoxicity in an engineered cardiac microtissue model","volume":"3","author":"Truitt","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"2026092607012748500_ehag609-B37","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaf1060","article-title":"Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload","author":"Gal\u00e1n-Arriola","year":"2026","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B38","doi-asserted-by":"publisher","first-page":"e75","DOI":"10.1161\/RES.0000000000000291","article-title":"Use of human induced pluripotent stem cell-derived cardiomyocytes in preclinical cancer drug cardiotoxicity testing: a scientific statement from the American Heart Association","volume":"125","author":"Gintant","year":"2019","journal-title":"Circ Res"},{"key":"2026092607012748500_ehag609-B39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00395-022-00918-7","article-title":"Doxorubicin induces cardiotoxicity in a pluripotent stem cell model of aggressive B cell lymphoma cancer patients","volume":"117","author":"Haupt","year":"2022","journal-title":"Basic Res Cardiol"},{"key":"2026092607012748500_ehag609-B40","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.jaccao.2023.11.008","article-title":"Functional validation of doxorubicin-induced cardiotoxicity-related genes","volume":"6","author":"Fonoudi","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B41","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.124.011876","article-title":"Insights from living myocardial slices into chemotherapy-induced cardiotoxicity: a novel ex vivo tool to guide clinical decision-making","volume":"18","author":"Kelters","year":"2025","journal-title":"Circ Heart Fail"},{"key":"2026092607012748500_ehag609-B42","doi-asserted-by":"publisher","first-page":"4262","DOI":"10.1111\/bph.70085","article-title":"Dexrazoxane protects against doxorubicin-induced cardiotoxicity in susceptible human living myocardial slices: a proof-of-concept study","volume":"182","author":"van der Geest","year":"2025","journal-title":"Br J Pharmacol"},{"key":"2026092607012748500_ehag609-B43","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1001\/jamacardio.2021.0038","article-title":"Screening for atrial fibrillation in the older population: a randomized clinical trial","volume":"6","author":"Gladstone","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026092607012748500_ehag609-B44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-025-14005-2","article-title":"Physical rehabilitation program for cardiorespiratory health and quality of life among breast cancer survivors in UAE: a randomized control trial","volume":"25","author":"Rashid","year":"2025","journal-title":"BMC Cancer"},{"key":"2026092607012748500_ehag609-B45","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.jaccao.2024.03.010","article-title":"Health literacy, individual and community engagement, and cardiovascular risks and disparities: JACC: CardioOncology state-of-the-art review","volume":"6","author":"Taylor","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B46","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.jaccao.2021.05.001","article-title":"Racial and ethnic disparities in cardio-oncology: a call to action","volume":"3","author":"Fazal","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.jaccao.2024.07.016","article-title":"Anthracycline cardiotoxicity in adult cancer patients: JACC: cardioOncology state-of-the-art review","volume":"6","author":"Camilli","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41514-024-00135-7","article-title":"A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging","volume":"10","author":"Linders","year":"2024","journal-title":"NPJ Aging"},{"key":"2026092607012748500_ehag609-B49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic variants associated with cancer therapy-induced cardiomyopathy","volume":"140","author":"Garcia-Pavia","year":"2019","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B50","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jaccao.2023.03.012","article-title":"Evaluation of senescence and its prevention in doxorubicin-induced cardiotoxicity using dynamic engineered heart tissues","volume":"5","author":"Linders","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B51","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s43018-020-0039-1","article-title":"A small-molecule allosteric inhibitor of BAX protects against doxorubicin-induced cardiomyopathy","volume":"1","author":"Amgalan","year":"2020","journal-title":"Nat Cancer"},{"key":"2026092607012748500_ehag609-B52","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/CIRCULATIONAHA.115.017443","article-title":"Doxorubicin blocks cardiomyocyte autophagic flux by inhibiting lysosome acidification","volume":"133","author":"Li","year":"2016","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B53","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s11010-023-04903-z","article-title":"Mandatory role of endoplasmic reticulum and its pentose phosphate shunt in the myocardial defense mechanisms against the redox stress induced by anthracyclines","volume":"479","author":"Sambuceti","year":"2024","journal-title":"Mol Cell Biochem"},{"key":"2026092607012748500_ehag609-B54","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the changes in cardiac structure and function in mice treated with anthracyclines using serial cardiac magnetic resonance imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026092607012748500_ehag609-B55","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jaccao.2024.12.004","article-title":"SGLT2i therapy prevents anthracycline-induced cardiotoxicity in a large animal model by preserving myocardial energetics","volume":"7","author":"Medina-Hern\u00e1ndez","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B56","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.jaccao.2024.02.005","article-title":"Anthracycline cardiotoxicity induces progressive changes in myocardial metabolism and mitochondrial quality control: novel therapeutic target","volume":"6","author":"D\u00edaz-Guerra","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B57","doi-asserted-by":"publisher","first-page":"E015782","DOI":"10.1161\/CIRCIMAGING.123.015782","article-title":"Impaired cardiac and skeletal muscle energetics following anthracycline therapy for breast cancer","volume":"16","author":"Gamble","year":"2023","journal-title":"Circ Cardiovasc Imaging"},{"key":"2026092607012748500_ehag609-B58","doi-asserted-by":"publisher","first-page":"432","DOI":"10.20455\/ros.2016.873","article-title":"Fluorescence-based assays for measuring doxorubicin in biological systems","volume":"2","author":"Kauffman","year":"2016","journal-title":"React Oxyg Species (Apex)"},{"key":"2026092607012748500_ehag609-B59","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s10549-021-06427-w","article-title":"Trastuzumab does not bind rat or mouse ErbB2\/neu: implications for selection of non-clinical safety models for trastuzumab-based therapeutics","volume":"191","author":"Lewis Phillips","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"2026092607012748500_ehag609-B60","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.toxlet.2018.01.001","article-title":"Modeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes","volume":"285","author":"Kurokawa","year":"2018","journal-title":"Toxicol Lett"},{"key":"2026092607012748500_ehag609-B61","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1093\/cvr\/cvad012","article-title":"PTX3 from vascular endothelial cells contributes to trastuzumab-induced cardiac complications","volume":"119","author":"Xu","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026092607012748500_ehag609-B62","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2020.115213","article-title":"Heart slice culture system reliably demonstrates clinical drug-related cardiotoxicity","volume":"406","author":"Miller","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"2026092607012748500_ehag609-B63","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s00280-015-2922-5","article-title":"Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous \u2018manual syringe\u2019 injection or intravenously in women with HER2-positive early breast cancer","volume":"77","author":"Quartino","year":"2016","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026092607012748500_ehag609-B64","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1097\/FJC.0000000000001157","article-title":"Trastuzumab-induced negative chronotropic and lusitropic effects in cynomolgus monkeys","volume":"79","author":"Ishizaka","year":"2022","journal-title":"J Cardiovasc Pharmacol"},{"key":"2026092607012748500_ehag609-B65","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.echo.2011.01.018","article-title":"The cardioprotective role of probucol against anthracycline and trastuzumab-mediated cardiotoxicity","volume":"24","author":"Walker","year":"2011","journal-title":"J Am Soc Echocardiogr"},{"key":"2026092607012748500_ehag609-B66","doi-asserted-by":"publisher","first-page":"3171","DOI":"10.1096\/fj.09-131383","article-title":"Cardiotoxic effects, or lack thereof, of anti-ErbB2 immunoagents","volume":"23","author":"Riccio","year":"2009","journal-title":"FASEB J"},{"key":"2026092607012748500_ehag609-B67","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.echo.2009.01.016","article-title":"Utility of tissue Doppler and strain rate imaging in the early detection of trastuzumab and anthracycline mediated cardiomyopathy","volume":"22","author":"Jassal","year":"2009","journal-title":"J Am Soc Echocardiogr"},{"key":"2026092607012748500_ehag609-B68","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1093\/eurheartj\/ehae047","article-title":"Ischaemic heart disease in patients with cancer","volume":"45","author":"Ameri","year":"2024","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B69","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1111\/bph.13725","article-title":"5-fluorouracil causes endothelial cell senescence: potential protective role of glucagon-like peptide 1","volume":"174","author":"Altieri","year":"2017","journal-title":"Br J Pharmacol"},{"key":"2026092607012748500_ehag609-B70","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1021\/ci0501746","article-title":"Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning","volume":"45","author":"Spasojevi\u0107","year":"2005","journal-title":"J Chem Inf Model"},{"key":"2026092607012748500_ehag609-B71","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1200\/JCO.2007.13.3934","article-title":"Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer","volume":"26","author":"Gamelin","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026092607012748500_ehag609-B72","doi-asserted-by":"publisher","first-page":"8661","DOI":"10.1038\/s41598-022-12735-y","article-title":"The effect of propolis on 5-fluorouracil-induced cardiac toxicity in rats","volume":"12","author":"Barary","year":"2022","journal-title":"Sci Rep"},{"key":"2026092607012748500_ehag609-B73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115686","article-title":"Effects of 5-fluorouracil on morphology, cell cycle, proliferation, apoptosis, autophagy and ros production in endothelial cells and cardiomyocytes","volume":"10","author":"Focaccetti","year":"2015","journal-title":"PLoS One"},{"key":"2026092607012748500_ehag609-B74","doi-asserted-by":"publisher","first-page":"33713","DOI":"10.1074\/jbc.R109.018481","article-title":"The 26 S proteasome: from basic mechanisms to drug targeting","volume":"284","author":"Navon","year":"2009","journal-title":"J Biol Chem"},{"key":"2026092607012748500_ehag609-B75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaccao.2022.12.005","article-title":"Cardiovascular toxicity of proteasome inhibitors: underlying mechanisms and management strategies: JACC: CardioOncology state-of-the-art review","volume":"5","author":"Georgiopoulos","year":"2023","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B76","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s00280-010-1283-3","article-title":"Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma","volume":"67","author":"Reece","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026092607012748500_ehag609-B77","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/107327480301000502","article-title":"Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers","volume":"10","author":"Richardson","year":"2003","journal-title":"Cancer Control"},{"key":"2026092607012748500_ehag609-B78","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1182\/blood-2018-06-858415","article-title":"Molecular mechanisms of carfilzomib-induced cardiotoxicity in mice and the emerging cardioprotective role of metformin","volume":"133","author":"Efentakis","year":"2019","journal-title":"Blood"},{"key":"2026092607012748500_ehag609-B79","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12012-015-9356-5","article-title":"Rutin attenuates carfilzomib-induced cardiotoxicity through inhibition of NF-\u03baB, hypertrophic gene expression and oxidative stress","volume":"17","author":"Imam","year":"2017","journal-title":"Cardiovasc Toxicol"},{"key":"2026092607012748500_ehag609-B80","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/cancers15072191","article-title":"Arginase inhibition mitigates bortezomib-exacerbated cardiotoxicity in multiple myeloma","volume":"15","author":"Paterek","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026092607012748500_ehag609-B81","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-24137-1","article-title":"Targeting arginase-1 exerts antitumor effects in multiple myeloma and mitigates bortezomib-induced cardiotoxicity","volume":"12","author":"Ramji","year":"2022","journal-title":"Sci Rep"},{"key":"2026092607012748500_ehag609-B82","doi-asserted-by":"publisher","first-page":"10956","DOI":"10.3390\/ijms222010956","article-title":"Elucidating carfilzomib\u2019s induced cardiotoxicity in an in vivo model of aging: prophylactic potential of metformin","volume":"22","author":"Efentakis","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2026092607012748500_ehag609-B83","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"key":"2026092607012748500_ehag609-B84","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"key":"2026092607012748500_ehag609-B85","doi-asserted-by":"publisher","first-page":"189","DOI":"10.3109\/15376516.2016.1143071","article-title":"Carfilzomib-induced cardiotoxicity mitigated by dexrazoxane through inhibition of hypertrophic gene expression and oxidative stress in rats","volume":"26","author":"Al-Harbi","year":"2016","journal-title":"Toxicol Mech Methods"},{"key":"2026092607012748500_ehag609-B86","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"key":"2026092607012748500_ehag609-B87","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1042\/CS20190139","article-title":"In vitro and in vivo investigation of cardiotoxicity associated with anticancer proteasome inhibitors and their combination with anthracycline","volume":"133","author":"Pokorna","year":"2019","journal-title":"Clin Sci"},{"key":"2026092607012748500_ehag609-B88","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12012-023-09785-7","article-title":"Molecular cardiotoxic effects of proteasome inhibitors carfilzomib and ixazomib and their combination with dexamethasone involve mitochondrial dysregulation","volume":"23","author":"Jannuzzi","year":"2023","journal-title":"Cardiovasc Toxicol"},{"key":"2026092607012748500_ehag609-B89","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1345\/aph.1Q422","article-title":"Protease inhibitor-associated QT interval prolongation","volume":"45","author":"Hunt","year":"2011","journal-title":"Ann Pharmacother"},{"key":"2026092607012748500_ehag609-B90","doi-asserted-by":"publisher","first-page":"e6257","DOI":"10.1371\/journal.pone.0006257","article-title":"Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia","volume":"4","author":"Hu","year":"2009","journal-title":"PLoS One"},{"key":"2026092607012748500_ehag609-B91","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1002\/9780470942390.mo140195","article-title":"Aging research using mouse models","volume":"5","author":"Ackert-Bicknell","year":"2015","journal-title":"Curr Protoc Mouse Biol"},{"key":"2026092607012748500_ehag609-B92","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1161\/CIRCULATIONAHA.120.049210","article-title":"Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase","volume":"142","author":"Xiao","year":"2020","journal-title":"Circulation"},{"key":"2026092607012748500_ehag609-B93","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/j.1755-5922.2011.00278.x","article-title":"Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function","volume":"30","author":"Blasi","year":"2012","journal-title":"Cardiovasc Ther"},{"key":"2026092607012748500_ehag609-B94","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/j.leukres.2010.01.004","article-title":"Imatinib does not induce cardiotoxicity at clinically relevant concentrations in preclinical studies","volume":"34","author":"Wolf","year":"2010","journal-title":"Leuk Res"},{"key":"2026092607012748500_ehag609-B95","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1002\/ejhf.58","article-title":"Ageing is a risk factor in imatinib mesylate cardiotoxicity","volume":"16","author":"Maharsy","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"2026092607012748500_ehag609-B96","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1177\/0192623308326151","article-title":"Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors","volume":"36","author":"Patyna","year":"2008","journal-title":"Toxicol Pathol"},{"key":"2026092607012748500_ehag609-B97","doi-asserted-by":"publisher","first-page":"4801","DOI":"10.1007\/s00204-025-04159-0","article-title":"Evaluating the use of rodents as in vitro, in vivo and ex vivo experimental models for the assessment of tyrosine kinase inhibitor-induced cardiotoxicity: a systematic review","volume":"99","author":"Gill","year":"2025","journal-title":"Arch Toxicol"},{"key":"2026092607012748500_ehag609-B98","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","article-title":"Radiotherapy toxicities: mechanisms, management, and future directions","volume":"405","author":"Verginadis","year":"2025","journal-title":"Lancet"},{"key":"2026092607012748500_ehag609-B99","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.ijrobp.2009.09.064","article-title":"Radiation-related heart disease: current knowledge and future prospects","volume":"76","author":"Darby","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092607012748500_ehag609-B100","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jaccao.2021.06.003","article-title":"Cardiovascular manifestations from therapeutic radiation: a multidisciplinary expert consensus statement from the international cardio-oncology society","volume":"3","author":"Mitchell","year":"2021","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B101","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.radonc.2020.08.007","article-title":"Radiation-induced risk of ischemic heart disease following breast cancer radiotherapy in Denmark, 1977\u20132005","volume":"152","author":"Laugaard Lorenzen","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026092607012748500_ehag609-B102","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1200\/JCO.2015.63.4444","article-title":"Radiation dose-response relationship for risk of coronary heart disease in survivors of Hodgkin lymphoma","volume":"34","author":"Van Nimwegen","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026092607012748500_ehag609-B103","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ijrobp.2018.12.044","article-title":"Is the importance of heart dose overstated in the treatment of non-small cell lung cancer? A systematic review of the literature","volume":"104","author":"Zhang","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092607012748500_ehag609-B104","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1158\/1078-0432.CCR-16-1164","article-title":"Found in translation: maximizing the clinical relevance of nonclinical oncology studies","volume":"23","author":"Spilker","year":"2017","journal-title":"Clin Cancer Res"},{"key":"2026092607012748500_ehag609-B105","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/ddr.21461","article-title":"Dose translation between laboratory animals and human in preclinical and clinical phases of drug development","volume":"79","author":"Nair","year":"2018","journal-title":"Drug Dev Res"},{"key":"2026092607012748500_ehag609-B106","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/0167-8140(90)90149-Q","article-title":"Time-dose factors in radiotherapy: a review of the human data","volume":"19","author":"Thames","year":"1990","journal-title":"Radiother Oncol"},{"key":"2026092607012748500_ehag609-B107","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20160441","article-title":"Tumour and normal tissue radiobiology in mouse models: how close are mice to mini-humans?","volume":"90","author":"Koontz","year":"2017","journal-title":"Br J Radiol"},{"key":"2026092607012748500_ehag609-B108","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3389\/fcvm.2020.00023","article-title":"Differences in expression of mitochondrial complexes due to genetic variants may alter sensitivity to radiation-induced cardiac dysfunction","volume":"7","author":"Schlaak","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"2026092607012748500_ehag609-B109","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.radonc.2020.04.018","article-title":"Plasma metabolite biomarkers predictive of radiation induced cardiotoxicity","volume":"152","author":"Unger","year":"2020","journal-title":"Radiother Oncol"},{"key":"2026092607012748500_ehag609-B110","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.ijrobp.2022.08.031","article-title":"Spatial gene expression changes in the mouse heart after base-targeted irradiation","volume":"115","author":"Walls","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092607012748500_ehag609-B111","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ijrobp.2023.08.011","article-title":"Incident atrial fibrillation and survival outcomes in esophageal cancer following radiotherapy","volume":"118","author":"Miller","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2026092607012748500_ehag609-B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110085","article-title":"Pulmonary vein dose and risk of atrial fibrillation in patients with non-small cell lung cancer following definitive radiotherapy: an NI-HEART analysis","volume":"192","author":"Walls","year":"2024","journal-title":"Radiother Oncol"},{"key":"2026092607012748500_ehag609-B113","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/j.jaccao.2024.07.005","article-title":"Cardiac substructure radiation dose and associations with tachyarrhythmia and bradyarrhythmia after lung cancer radiotherapy","volume":"6","author":"Atkins","year":"2024","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B114","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2020.05.004","article-title":"Cardiovascular mortality and morbidity following radical radiotherapy for lung cancer: is cardiovascular death under-reported?","volume":"146","author":"Sun","year":"2020","journal-title":"Lung Cancer"},{"key":"2026092607012748500_ehag609-B115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-019-0099-9","article-title":"The emerging treatment landscape of targeted therapy in non-small-cell lung cancer","volume":"4","author":"Yuan","year":"2019","journal-title":"Signal Transduct Target Ther"},{"key":"2026092607012748500_ehag609-B116","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"2026092607012748500_ehag609-B117","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"key":"2026092607012748500_ehag609-B118","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1016\/j.jacc.2018.02.037","article-title":"Myocarditis in patients treated with immune checkpoint inhibitors","volume":"71","author":"Mahmood","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2026092607012748500_ehag609-B119","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/S0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"The Lancet"},{"key":"2026092607012748500_ehag609-B120","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","article-title":"Risk factors for immune checkpoint inhibitor\u2013mediated cardiovascular toxicities","volume":"25","author":"Yousif","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"2026092607012748500_ehag609-B121","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1158\/2159-8290.CD-20-0856","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor\u2013associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","journal-title":"Cancer Discov"},{"key":"2026092607012748500_ehag609-B122","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/s41586-022-05432-3","article-title":"T cells specific for \u03b1-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","journal-title":"Nature"},{"key":"2026092607012748500_ehag609-B123","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","article-title":"Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape","volume":"72","author":"Woo","year":"2012","journal-title":"Cancer Res"},{"key":"2026092607012748500_ehag609-B124","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1093\/eurheartj\/ehab430","article-title":"Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy","volume":"43","author":"Michel","year":"2022","journal-title":"Eur Heart J"},{"key":"2026092607012748500_ehag609-B125","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2019.3113","article-title":"Factors associated with immune checkpoint inhibitor-related myocarditis","volume":"5","author":"Zamami","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026092607012748500_ehag609-B126","doi-asserted-by":"publisher","first-page":"6640","DOI":"10.1038\/s41467-024-50996-5","article-title":"Gasdermin-E-mediated pyroptosis drives immune checkpoint inhibitor-associated myocarditis via cGAS-STING activation","volume":"15","author":"Sun","year":"2024","journal-title":"Nat Commun"},{"key":"2026092607012748500_ehag609-B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"2026092607012748500_ehag609-B128","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2337\/db17-1467","article-title":"Improved murine MHC-deficient HLA transgenic NOD mouse models for type 1 diabetes therapy development","volume":"67","author":"Racine","year":"2018","journal-title":"Diabetes"},{"key":"2026092607012748500_ehag609-B129","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.4049\/jimmunol.2300841","article-title":"Murine MHC-deficient nonobese diabetic mice carrying human HLA-DQ8 develop severe myocarditis and myositis in response to anti-PD-1 immune checkpoint inhibitor cancer therapy","volume":"212","author":"Racine","year":"2024","journal-title":"J Immunol"},{"key":"2026092607012748500_ehag609-B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2025.119147","article-title":"Immune checkpoint inhibitors: unravelling atherosclerotic cardiovascular risk","volume":"403","author":"Gray","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026092607012748500_ehag609-B131","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","article-title":"Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC state-of-the-art review","volume":"79","author":"Vuong","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"2026092607012748500_ehag609-B132","doi-asserted-by":"publisher","first-page":"119219","DOI":"10.1016\/j.atherosclerosis.2025.119219","article-title":"Accelerated atherosclerosis associated with immune checkpoint inhibitors: a systematic review and meta-analysis of pre-clinical studies","volume":"405","author":"Strijdhorst","year":"2025","journal-title":"Atherosclerosis"},{"key":"2026092607012748500_ehag609-B133","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nrd4597","article-title":"The pharmacology of second-generation chimeric antigen receptors","volume":"14","author":"Van Der Stegen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"2026092607012748500_ehag609-B134","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026092607012748500_ehag609-B135","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026092607012748500_ehag609-B136","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"key":"2026092607012748500_ehag609-B137","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.15252\/emmm.201607485","article-title":"Clinical development of CAR T cells\u2014challenges and opportunities in translating innovative treatment concepts","volume":"9","author":"Hartmann","year":"2017","journal-title":"EMBO Mol Med"},{"key":"2026092607012748500_ehag609-B138","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) T cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int J Mol Sci"},{"key":"2026092607012748500_ehag609-B139","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-Seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026092607012748500_ehag609-B140","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41576-023-00586-w","article-title":"Best practices for single-cell analysis across modalities","volume":"24","author":"Heumos","year":"2023","journal-title":"Nat Rev Genet"},{"key":"2026092607012748500_ehag609-B141","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41596-020-00409-w","article-title":"Tutorial: guidelines for the computational analysis of single-cell RNA sequencing data","volume":"16","author":"Andrews","year":"2021","journal-title":"Nat Protoc"},{"key":"2026092607012748500_ehag609-B142","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1101\/gr.136184.111","article-title":"ChIP-seq guidelines and practices of the ENCODE and modENCODE consortia","volume":"22","author":"Landt","year":"2012","journal-title":"Genome Res"},{"key":"2026092607012748500_ehag609-B143","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s43586-024-00359-7","article-title":"Systematic review and meta-analysis of preclinical studies","volume":"4","author":"Ineichen","year":"2024","journal-title":"Nat Rev Methods Primers"},{"key":"2026092607012748500_ehag609-B144","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.radonc.2022.04.030","article-title":"Murine models of radiation cardiotoxicity: a systematic review and recommendations for future studies","volume":"173","author":"Walls","year":"2022","journal-title":"Radiother Oncol"},{"key":"2026092607012748500_ehag609-B145","doi-asserted-by":"publisher","first-page":"2365","DOI":"10.1056\/NEJMsb2512695","article-title":"FDA\u2019s new plausible mechanism pathway","volume":"393","author":"Prasad","year":"2025","journal-title":"N Engl J Med"},{"key":"2026092607012748500_ehag609-B146","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jaccao.2025.05.012","article-title":"Mismatch between preclinical cardio-oncology and clinical oncology research","volume":"7","author":"Cagnazzo","year":"2025","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B147","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.jaccao.2022.07.005","article-title":"Permissive cardiotoxicity: the clinical crucible of cardio-oncology","volume":"4","author":"Porter","year":"2022","journal-title":"JACC CardioOncol"},{"key":"2026092607012748500_ehag609-B148","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013754","article-title":"Reverse cardio-oncology: cancer development in patients with cardiovascular disease","volume":"9","author":"Aboumsallem","year":"2020","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag609\/70972702\/ehag609.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article-pdf\/doi\/10.1093\/eurheartj\/ehag609\/70972702\/ehag609.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:01:36Z","timestamp":1790420496000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/advance-article\/doi\/10.1093\/eurheartj\/ehag609\/8786400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,7]]},"references-count":148,"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehag609","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,7]]},"article-number":"ehag609"}}